SR 12813

Key Product Details

Product Description

SR 12813 is a pregnane X receptor (PXR) agonist (EC₅₀ values are 200 and 700 nM for human and rabbit PXR respectively). Activates the farnesoid X receptor (FXR) at μM concentrations. Displays hypocholesterolemic activity via enhanced degradation of HMG-CoA reductase.

Product Specifications for SR 12813

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SR 12813

The following data is based on the product molecular weight 504.53.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.98 mL	9.91 mL	19.82 mL
5 mM	0.40 mL	1.98 mL	3.96 mL
10 mM	0.20 mL	0.99 mL	1.98 mL
50 mM	0.04 mL	0.20 mL	0.40 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 7 publications citing the usage of this product.

• Lemaire Discovery of a highly active ligand of human pregnane X receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity. Mol.Pharmacol. 2007 PMID: 17573484
• Jones The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol.Pharmacol.
• Berkhout The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase J.Biol.Chem. 1996 PMID: 8662919

Product Documents for SR 12813